FYN

Across TCGA pan-cancer cohorts, FYN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FYN data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FYN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FYN expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LUAD are the cancer types where FYN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	15	view →
GBM	DFS	Median	All	0.821	0.671	.006	9	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →
CCRCC	DFS	Median	III,IV	0.809	0.571	.040	1	view →
LSCC	DFS	Tertile	II,III,IV	0.573	0.886	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FYN–PDAC (DFS)

Open the PDAC breakdown →